Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (1488)	12/18/2008 12:13:50 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

Too bad. It was a long shot, but the risk/reward ratio looked pretty good to me. I bailed at the open yesterday and was lucky to exit at $0.35/share. The mean and median average time that patients in the trial were receiving treatment was about 5-1/4 hrs after the onset of the stroke. That's a very tough population in which to demonstrate significant benefit. It will be interesting to see the data analysis for the small subset of patients, in Poland, who were given Viprenex within the first 3 hrs after onset. But from an investment perspective, the best hope for the remaining NTII stockholders is that the company shut down operations and liquidate the remaining assets. Marc